This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
XtalPi has entered a strategic partnership with CK LifeSciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.
The Indian lifesciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, big data, internet of things (IoT) and blockchain into their research and development efforts.
As the Union Budget approaches, the lifesciences sector anticipates substantial support to enhance innovation and investment in the development of new chemical entities (NCEs) and new biological entities (NBEs). The lifesciences sector in India has shown remarkable resilience […]
The expansion will also contribute to building the province of Ontarios position as a global hub for lifesciences and biotechnology. In 2023, the pharma giant launched the new Alexion, AstraZeneca Rare Disease Development Hub in Mississauga. The acquisition was one of the largest research investments in a Canadian biotech firm.
GSK has entered a strategic partnership with Wave LifeSciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development.
Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.
Two drugs developed by Wave LifeSciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.
The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance lifesciences.
Viatris has signed definitive agreements to acquire Oyster Point Pharma and Famy LifeSciences in a deal totalling nearly $700m-$750m in cash to establish an ophthalmology franchise. A commercial-stage biopharmaceutical firm, Oyster Point discovers, develops and commercialises therapies for treating ophthalmic ailments.
From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables lifesciences teams to collaborate efficiently and effectively in 2023. Simplicity and technology intersect to streamline drug development.
Join us as we celebrate a major milestone the 200th episode of the Xtalks LifeScience Podcast! From groundbreaking biotech innovations to exclusive interviews with lifescience industry innovators and leaders, we’ve covered it all. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
This week, were celebrating a significant milestone: the release of our 200th episode of the Xtalks LifeScience Podcast ! We’re excited to continue our journey by bringing you more in-depth conversations with industry leaders, highlighting the innovations and trends that shape the future of lifesciences.
This prestigious acknowledgment places Cloudbyz among the top-performing companies globally, known for delivering scalable and intuitive CTMS solutions that empower clinical research teams. Our mission is to enable faster, more efficient trials, ultimately supporting the delivery of life-saving therapies.”
In the lifesciences sector, one country is significantly outstripping others for FDI. Data shows that almost 40% of all lifesciences subsidiaries are located in the US. After all, around a third of the world’s leading lifesciences corporations have their headquarters in the country. Industry clusters.
From the Human Genome Project to contemporary drug development, collaboration is critical to the lifesciences. It is also an important factor in the success of lifesciences clusters, where a high concentration of pharmaceutical or medical device companies can all be found in one district, city or region.
Forge Biologics and global lifesciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.
It is no secret that Canada boasts a strong and competitive lifesciences sector. Within Canada, one province has often stood out as the place to be for cutting-edge lifesciences innovation. These factors have combined to make Ontario a leading force for medical research and innovation. Again, this is nothing new.
Discover the role of GenAI in lifesciences in 2024. Explore how artificial intelligence and machine learning techniques like GenAI are revolutionising drug development, diagnostics, and research. Learn how industry leaders, including Google, are leveraging GenAI to advance healthcare and enhance patient outcomes.
November is Pancreatic Cancer Awareness Month , a time dedicated to increasing public understanding of this challenging disease, supporting patients and their families and advancing research for better treatment options. For this reason, researchers are working hard to find new methods to identify pancreatic cancer sooner.
In the lifesciences, countless Black scientists, researchers and medical professionals have made groundbreaking discoveries that have significantly advanced our understanding of biology and medicine. Wright’s work on patient biopsy samples led to the groundbreaking use of chemotherapy as a viable cancer treatment.
As we step into 2024, the lifesciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.
Lifescience podcasts have emerged as an invaluable tool for building connections with audiences in the digital era. Furthermore, we’ll explore the unique advertising opportunities that this platform offers, positioning brands at the forefront of the lifescience industry. The result?
Moderna has signed an agreement with IBM to explore quantum computing and generative artificial intelligence (AI) for advancing and expediting its mRNA research. IBM will also provide its knowledge to help Moderna explore the potential use cases of quantum technologies in lifesciences.
Especially as we exited the blockbuster drug period of psychiatric development and trials were failing with huge placebo effects, I think we started realizing that the patients going into trials were not the real-world patients that were getting treated with drugs in the clinic.
Panagos, an industry veteran with extensive experience in the healthcare and lifesciences sector, takes over from Colin Shannon, who served as CEO for one year following the company’s acquisition by a consortium of private equity firms. Shannon has now been appointed Executive Chairman of Syneos.
Optum LifeSciences expert provides insights on the latest trends. For manufacturers developing GLP-1s or in the market, its invaluable to understand the nuances of how real-world evidence (RWE) can be harnessed to demonstrate the clinical and economic value of weight loss medications.
This episode features an interview with Yang Liu, PhD, founder, chairman, CEO and chief scientific officer; and Abid Ansari, MBA, Chief Financial Officer at OncoC4 , a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Meanwhile, others are researching the link between gene variation and different responses to treatments.
Established in 2018, CytoMed is a biotechnology firm that originated from the Agency for Science, Technology and Research (A*STAR), Singapore’s premier public sector research and development agency. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
David Young, founder and President R&D at Processa Pharmaceuticals, a clinical-stage pharmaceutical company developing personalized approaches to cancer treatments with a focus on next generation chemotherapy drugs with improved safety and efficacy. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
Consistency is a key factor in any successful lifescience content marketing strategy. Maintaining consistency throughout the content you develop is essential to establish credibility and loyalty. Let’s explore why and how consistency can play a vital role in the success of B2B lifescience content marketing.
This Act is poised to significantly change the clinical trials landscape within the lifesciences sector. As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation. first appeared on CLOUDBYZ.
In the dynamic world of lifesciences, where innovation is paramount, the integration of cutting-edge technologies is crucial for accelerating clinical operations and driving breakthroughs in healthcare. Salesforce’s recent announcement of its LifeSciences Cloud marks a significant stride towards this goal.
BioLink LifeSciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. The trial will also lay the ground for additional trials for acute and long Covid in the US.
This is the latest episode of the free DDW narrated podcast, titled Critical tools that support drug discovery and development, which covers two articles written for DDW Volume 24 Issue 3, Summer 2023.They and Big data: Charting a new path to drug discovery and development .
She hopes her work at CTTI will influence the development of a clinical trial system that is more efficient, inclusive and better aligned with patient needs. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode. Tune in to learn how CTTI is leading efforts to reshape clinical trials.
Dr. Perkins has also led the development and implementation of innovative digital educational outreach campaigns for primary care physicians. Tune into the episode to hear more about the latest trial data for finerenone in heart failure and the landscape of heart failure research.
The Foundation for the National Institutes of Health (FNIH) has announced its plans to prioritise eight rare diseases to provide industry standards for manufacturing, preclinical testing and product analytical testing for gene therapy development.
Across every corner of the industry, from research and development to patient engagement, AI, and most recently generative AI (GenAI), is driving profound change.
World Pneumonia Day 2024 provides an opportunity to examine the latest advances in pneumonia treatment and prevention — and the role that healthcare and lifesciences industries play in reducing its global impact. These innovations can help prevent viral pneumonia complications in high-risk groups.
The same is true in lifesciences. As the technology develops, however, it will offer more opportunities to expedite drug discovery processes, streamline clinical trials, and speed up regulatory approvals. MGI puts the value of this contribution to clinical development at $15 billion to $25 b illion.
In this episode, Ayesha spoke with Sarah Averill Lott, MPH, CPH, Research Lead at Digital Medicine Society (DiMe) and Diane Stephenson, PhD, Executive Director at the Critical Path for Parkinson (CPP) at the Critical Path Institute. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics , a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content